SRNE Sorrento Therapeutics Inc.

3.52
+0.26  (+8%)
Previous Close 3.26
Open 3.35
Price To Book 12.57
Market Cap 579,152,052
Shares 164,531,833
Volume 4,477,027
Short Ratio
Av. Daily Volume 4,910,924
Stock charts supplied by TradingView

NewsSee all news

  1. Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", or the "Company")), confirmed today that on November 23, 2019, it received an unsolicited, non-binding term

  2. Sorrento CEO to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, will participate in upcoming investor conferences in

  3. Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

    SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento's research team will

  4. Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering

    SAN DIEGO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento")), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into

  5. Sorrento Therapeutics Announces $25 Million Registered Direct Offering

    SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento")), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced February 28, 2018.
ZTlido (lidocaine patch 1.8%)
Pain associated with post-herpetic neuralgia (PHN)
Data analysis suggests that Cynviloq meets the bioequivalence (BE) criteria for both total and unbound paclitaxel
Cynviloq
Cancer
Phase 1 data due 4Q 2019 / 1Q 2020.
Anti-CD38 CAR-T
Multiple Myeloma
Pivotal trial to commence 2H 2019.
anti-CEA CAR-T cells
Pancreatic cancer
Phase 1b trial to conclude in 2019 with Phase 3 trial to commence 1H 2020.
Resiniferatoxin
Osteoarthritis Knee
Phase 2 trial to be initiated 2H 2019.
IMC-001 (STI-3031)
Solid tumors
Phase 3 top-line data due 1H 2020.
SP-102
Lumbosacral radicular pain (sciatica)

Latest News

  1. Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", or the "Company")), confirmed today that on November 23, 2019, it received an unsolicited, non-binding term

  2. Sorrento CEO to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, will participate in upcoming investor conferences in

  3. Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

    SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento's research team will

  4. Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering

    SAN DIEGO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento")), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into

  5. Sorrento Therapeutics Announces $25 Million Registered Direct Offering

    SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento")), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into

  6. Scilex Announces New Medicaid Agreements with CA & FL

    PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE), is excited to announce that its subsidiary, Scilex

  7. Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

    PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in May of this year.

  8. Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

    SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE), announced that it has confidentially submitted a draft

  9. CBD Products Continue to Reap the Benefits of Legalization

    NEW YORK, Sept. 6, 2019 /PRNewswire/ -- The hemp industry has grown significantly over recent years as cannabis legalization has become more prominent. Notably, with the passage of the U.S. Farm Bill, the industry is

  10. Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates

    SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment conferences